Polysymnography Sleep Studies

(Phase II-IV); 13 Beds

CCT is the leader in sleep research and developing new therapies to treat insomnia and promote restorative sleep.

 

Our two sleep centers have a total of 13 beds dedicated to research, and our certified technicians and senior sleep staff have decades of experience.

Our sleep environments meet AASM accreditation standards and are staffed with Registered Polysomnographic (PSG) Technicians who lead, score and monitor the quality of data acquisition. All of our beds are video monitored, and feature Sandman 7.1 software for data capture, processing, and reporting/transmission.

We have completed over 35 clinical trials in multiple sleep-related indications and have experience conducting PSG, Non-PSG, MSLT (multiple sleep latency test), Transient Insomnia, and MWT studies. Other areas of sleep expertise include chronic insomnia, sleep apnea, shift worker disorder, restless legs syndrome, pain impact on sleep structure, and the evaluation of non-sleep medications on sleep architecture.

San Diego
Our San Diego site, established in 2002, has seven beds for protocol design and other consultative research services. CCT's proven methods of recruitment, advertising, enrollment, training, and quality assurance systems not only ensure high quality, but also exceed Sponsor expectations. The site conducts Phase II-IV studies and specializes in developing small pilot and proof of concept studies.

Glendale
This site, located in our wing of the Glendale Adventist Hospital, is wholly-owned and operated by CCT. The sleep center can be used to support drug development across Phase I-IV and provide you with a unique tool for evaluations of a novel compound. Changes in sleep architecture can be quantified, used as a surrogate endpoint, or as a tool to assess the impact of drugs on CNS physiological processes.

Nowhere else in the United States, except at the NIMH, can you combine Dynabridging (continuous Cerebral Spinal Fluid sampling), Polysomnography/EEG measures, and a skilled research team to determine the maximum tolerated dose selected patient populations. For many drugs where quantitative brain imaging is not available, PSG and CSF evaluations provide the necessary window into the brain, to determine the potentially effective dose that will be evaluated in subsequent clinical studies. PSG and CSF sampling also provide strong corroborative evidence for drug effectin trials where brain imaging is needed.

Click here to contact our staff for more information on CCT’s sleep studies.

Related Links